|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.7 ILa | +3.85% |
|
+3.85% | +3.85% |
Dec 18 (Reuters) - Can Fite Biopharma Ltd:
* CAN-FITE RECEIVED FDA POSITIVE RESPONSE TO PSORIASIS PEDIATRIC PLAN
* CAN FITE BIOPHARMA - PLAN SUBMITTED TO ALLOW ENROLLMENT OF CHILDREN WITH PSORIASIS TO CAN-FITE'S UPCOMING PHASE 3 PIVOTAL CLINICAL PSORIASIS STUDIES Source text for Eikon: Further company coverage:
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,743 PTS | +2.11% | +3.03% | - | ||
| 2.7 ILa | +3.85% | +3.85% | 10.36M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +3.85% | 10.36M | |
| -3.45% | 87.17B | |
| +1.97% | 40.1B | |
| +57.86% | 25.12B | |
| -14.82% | 15.59B | |
| -8.82% | 12B | |
| -16.29% | 11.8B | |
| -41.58% | 11.8B | |
| +6.89% | 8.81B | |
| -10.53% | 8.24B |
CAN-FITE BIOPHARMA LTD. 
